SAN DIEGO–(BUSINESS WIRE)–$ARCT #ClinicalTrial–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA…
Autor: Press Room
35 years of experience in the field of communications specialized in various business areas, such as administration, marketing, writing, public relations and more.
KBRA Assigns Preliminary Ratings to BX 2024-BIO2
NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA announces the assignment of preliminary ratings to four classes of BX 2024-BIO2, a…
University of Phoenix Leaders Join Proceedings of 2024 AACRAO Technology & Transfer Virtual Summit
Presentations highlight innovative approaches to credit mobility, program deployment and information technology in higher education PHOENIX–(BUSINESS…
Toshiba Launches New Series of eFuse ICs, Electronic Fuses That Can Be Used Repeatedly
– Introducing the compact, high-voltage “TCKE9 Series” – KAWASAKI, Japan–(BUSINESS WIRE)–Toshiba Electronic Devices & Storage Corporation…
AV Access Unveils Revolutionary eShare W80 Wireless Conferencing System at InfoComm Asia 2024 in Thailand
BANGKOK–(BUSINESS WIRE)–#avaccess–AV Access, a leading provider of Pro AV and AV over IP solutions, is excited…
Ardent Health Announces Pricing of Initial Public Offering
BRENTWOOD, Tenn.–(BUSINESS WIRE)–Ardent Health Partners, Inc. (f/k/a Ardent Health Partners, LLC and collectively, “Ardent Health”) today…
FICO Survey: 1 in 3 Malaysians Reject Bank, Credit Card Applications Over Complex ID Checks
In a digital-first world, identity verification must not hinder new business KUALA LUMPUR, Malaysia–(BUSINESS WIRE)–FICO (NYSE:…
Loci Orthopaedics Closes €12.8 Million Series A Financing
Company developing its innovative InDx Implant System for thumb base joint arthritis Focused on a painful…
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus…
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
– After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss…